Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond

Overview of attention for article published in Frontiers in immunology, June 2018

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 33,076 followers.

RT @FrontImmunol: Buder-Bakhaya and Hassel discuss #Biomarkers for Clinical Benefit of #immunecheckpoint Inhibitor Treatment Read & downl…

RT @FrontImmunol: Buder-Bakhaya and Hassel discuss #Biomarkers for Clinical Benefit of #immunecheckpoint Inhibitor Treatment Read & downl…

Buder-Bakhaya and Hassel discuss #Biomarkers for Clinical Benefit of #immunecheckpoint Inhibitor Treatment Read & download #OpenAccess the Review at https://t.co/hpcGlf3z7i #Immunotherapy #melanoma #PD-1 https://t.co/L5T3EsG98b

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond. https://t.co/LxEFClrhoT

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.